Back

Effect of bivalirudin vs unfractionated heparin in transcatheter aortic valve implantation with balloon-expandable valves. The BRAVO-3 trial

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 1 - Percutaneous structural heart interventions Percutaneous / endovascular treatment ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Axel Hp Linke

Heart Center - University Hospital Dresden, Dresden (Germany)

18 More presentations in this session

Presentation thumbnail
Comparison of outcomes between nonagenarian and younger patients undergoing transcatheter aortic valve replacement (TAVR) with the LOTUS valve.
Doctor S. Ramkumar (Melbourne, AU)
Abstract Slides
Presentation thumbnail
Transradial versus the transfemoral approach in alcohol septal ablation
Doctor T. Lefevre (Massy, FR)
Abstract Slides
Presentation thumbnail
Long term follow up after transcatheter tricuspid valve-in-valve replacement using Edwards Sapien XT valve.
Doctor R. Scarsini (Verona, IT)
Abstract Slides
Presentation thumbnail
5 years after percutaneous edge-to-edge mitral valve repair, what has happened?
Mr F. Kortlandt (Nieuwegein, NL)
Abstract Slides
Presentation thumbnail
Is multiparametric FRANCE-2 score better than EuroSCORE II and STS PROM in predicting early mortality after transcatheter aortic valve implantation?
Doctor J. Carmo (Carnaxide, PT)
Abstract

Access the full session

Session thumbnail
Poster session 1 - Percutaneous structural heart interventions

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources